Saturday, 18 November 2017

USFDA gives final approval to Bupropion Hydrochloride ER tablets by Jubilant Life Science

10 July 2017 | News

This is the fourth approval the company has received from the USFDA during the current financial year

Source: Pixabay

Source: Pixabay

Jubilant life science has recently announced that it has received Abbreviated New Drug Application (ANDA) final approval for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg, the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.

This is the fourth approval the company has received from the USFDA during the current financial year.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Are Indian drug firms still cautious of executing big mergers & acquistions?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls